news
Decibel Therapeutics submits IND application for hearing loss gene therapy candidate
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.
List view / Grid view
Biotherapeutics
article
Drug Target Review Synthetic Biology ebook 2022
Within this ebook are features on synthetic biology, covering synthetic biotics and their potential to treat a wide range of diseases and conditions, while another piece examines the therapeutic directions the synthetic biology field will likely take in the future.
article
Monoclonal antibodies as a strategy to fight cancer
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
article
Drug Target Review Antibodies ebook 2022
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
news
Chicken eggs used to produce SARS-CoV-2 antibodies
Researchers in the US have found that antibodies to the SARS-CoV-2 Spike protein can be produced in hen eggs.
article
Cell line development tactics and strategies for faster Investigational New Drug timelines
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
article
Neutralising SARS-CoV-2 with intranasally-delivered antibodies
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
article
Emerging trends in biotherapeutic development
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
article
The growth of cell line development
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
news
CAR T-cell implant effective at attacking cancer in pre-clinical study
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
article
Drug Target Review – Issue 1 2022
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
news
Automated plasmid purification workflow developed for mammalian cell expression-quality DNA
Eli Lilly scientists report that they have designed, qualified and enabled a high-throughput plasmid purification and quantification workstation.
podcasts
Episode 6 – mAbs and SARS-CoV-2 with Dr Carter Mitchell & Dr Sharath Madasu, Kemp Proteins
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
news
Novel CAR T-cell therapy for B-cell cancers shows promise in vivo
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
whitepaper
Product hub: Introducing the latest addition to Thermo Fisher Scientific’s genome editing portfolio – InvitrogenTM TrueCutTM HiFi Cas9 Protein!
Read about the latest addition Invitrogen™ TrueCut™ HiFi Cas9 Protein to support your application and research goals.
